Clinical trials
T Cells clinical trials
Below are recruiting t cells clinical trials, each written for real people, not researchers. We’re tracking 5,682 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07229729RecruitingPhase 2
Combination therapy for resectable lung cancer
This trial tests a new drug, SHR-A2102, combined with other treatments for people with non-small cell lung cancer that can be removed with surgery. It aims to improve outcomes by using multiple therapies together.
Guangzhou, GuangdongAges 18–70 - NCT07231068RecruitingPhase 1/Phase 2
Dositinib tablets for advanced lung cancer with EGFR mutation
This trial tests a new targeted therapy, Dositinib, for people with advanced non-small cell lung cancer that has an EGFR mutation and has stopped responding to earlier EGFR-targeted drugs. It aims to find the best dose and see how well it shrinks tumors.
BeijingAges 18–75 - NCT07231445RecruitingPhase 1
ZG006 with immunotherapy for extensive small cell lung cancer
This trial tests a new drug, ZG006, combined with standard immunotherapy (PD-1/PD-L1 inhibitors) for people with advanced small cell lung cancer that hasn't been treated before. The goal is to find out if this combination works better than the current standard care.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07232420RecruitingPhase 1
Study of BL-M24D1 for advanced lung cancer and other solid tumors
This trial tests a new drug, BL-M24D1, for people with advanced non-small cell lung cancer or other solid tumors that have spread or cannot be removed by surgery. The goal is to see if the drug is safe and effective.
Guangzhou, GuangdongAges 18 years+ - NCT07232524RecruitingPhase 1
BL-M24D1 for advanced head and neck and other solid tumors
This study tests a new drug called BL-M24D1 in people with head and neck cancer or other solid tumors that have spread or cannot be surgically removed. The goal is to see if the drug is safe and can help shrink tumors.
Chengdu, SichuanAges 18 years+ - NCT07236762RecruitingPhase 1
YTS109 cell therapy for severe autoimmune diseases
This trial tests a new cell therapy called YTS109 for people with severe autoimmune diseases like lupus, Sjögren's syndrome, systemic sclerosis, inflammatory myopathy, vasculitis, and antiphospholipid syndrome. It's for those whose disease hasn't improved with standard treatments.
BengbuAges 18–65 - NCT07236801RecruitingPhase 1
Cell therapy for hard-to-treat autoimmune diseases
This trial tests a new cell therapy called YTS109 for people with several autoimmune diseases that have not improved with standard medications. It aims to see if this treatment can help control the disease when other treatments have failed.
Xuzhou, JiangsuAges 18–65 - NCT07239895RecruitingEarly Phase 1
Stem cell treatment for children with bronchiolitis obliterans
This early trial tests if airway basal stem cells can help children with a serious lung condition called bronchiolitis obliterans. It aims to improve lung function and reduce the need for oxygen or breathing support.
ShanghaiAges 4 weeks–18 years - NCT07240610Recruiting
Radiation and immunotherapy for kidney cancer that has spread
This trial tests whether adding a special type of radiation to your current immunotherapy can help shrink kidney cancer tumors that have stopped responding or are stable. The goal is to see if the radiation can boost the immune system's ability to fight cancer elsewhere in the body.
Chūō, YamanashiAges 18 years+ - NCT07241585Recruiting
Vitamin D and light therapy for skin cancer
This trial tests whether taking vitamin D before a special light therapy (photodynamic therapy) can help your body fight nonmelanoma skin cancers like basal or squamous cell cancer. You may join if you are scheduled for surgery to remove a skin tumor.
Cleveland, OhioAges 18 years+ - NCT07246096RecruitingEarly Phase 1
CAR-T cell therapy for autoimmune diseases
This trial tests a new CAR-T cell treatment for people with certain autoimmune diseases that have not responded to standard therapies. The treatment uses your own immune cells modified to target and attack disease-causing cells.
ShanghaiAges 18–70 - NCT07246577Recruiting
Improving diagnosis and monitoring in giant cell arteritis
This study uses ultrasound, a biopsy of the temple artery, and blood tests to improve how giant cell arteritis (GCA) is diagnosed, monitored, and predicted. It may help doctors find better ways to manage this condition.
GothenburgAges 18 years+ - NCT07247188RecruitingPhase 3
Pneumococcal vaccine study for children with sickle cell disease
This trial tests a single dose of a new pneumococcal vaccine (21-valent) in children and teens with sickle cell disease. It aims to see if the vaccine can help protect against serious infections caused by pneumococcus bacteria, which are especially dangerous for people with SCD.
Atlanta, GeorgiaAges 2–17 - NCT07248176Recruiting
Universal CAR-T therapy for multiple myeloma
This trial tests a universal CAR-T cell therapy (made from donated cells) for multiple myeloma that has come back after at least two prior treatments. It may be an option if your cancer cells have a specific marker called BCMA and you have not had certain prior therapies.
ShanghaiAges 18 years+ - NCT07249372RecruitingPhase 2
DRP-104 for a specific type of advanced lung cancer
This trial tests a new drug, DRP-104, for people with advanced non-small cell lung cancer that has a change in the NFE2L2 or KEAP1 genes. It is for people whose cancer has gotten worse after standard treatments like chemotherapy and immunotherapy.
New York, New YorkAges 18 years+ - NCT06234904RecruitingPhase 1
IBR733 cell therapy for acute myeloid leukemia
This trial tests a new cell treatment called IBR733 for people with acute myeloid leukemia (AML) that has come back or not responded to other treatments. The goal is to see if it is safe and helps fight the leukemia.
Suzhou, JiangsuAges 18–74 - NCT07169734RecruitingPhase 1/Phase 2
ALE.P03 for advanced CLDN1-positive solid tumors
This trial tests a new drug, ALE.P03, for people with advanced or metastatic solid tumors that have a certain protein (CLDN1). The drug is given alone (monotherapy) to see if it can shrink tumors or slow their growth.
Phoenix, ArizonaAges 18 years+ - NCT07087158RecruitingPhase 2
IBR854 plus pazopanib vs pazopanib for advanced kidney cancer
This trial tests a new combination therapy (IBR854 plus pazopanib) against pazopanib alone for people with advanced clear cell kidney cancer who haven't had prior treatment. It aims to see if the combination works better.
ShanghaiAges 18 years+ - NCT07254585RecruitingPhase 2
SYS6010 plus enlonstobart for head and neck cancer
This trial is testing a new combination treatment, SYS6010 plus enlonstobart, for people with head and neck squamous cell carcinoma that has come back or spread. It aims to see if this combination works better than enlonstobart alone.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07254754RecruitingPhase 2
CAR-T cell therapy for late-relapse aggressive lymphoma
This trial tests a special immune cell therapy (CAR-T cells) for people with a type of aggressive lymphoma that returned more than a year after first treatment. It aims to see if this therapy can help control the cancer again.
A Coruña, A CoruñaAges 18 years+ - NCT07257510Recruiting
Pomalidomide plus two other drugs for untreated Mantle Cell Lymphoma
This trial tests a combination of three drugs (pomalidomide, orelabrutinib, and zuberitamab) in people with Mantle Cell Lymphoma who have not yet received treatment. It aims to see if this combination works better than standard therapy, especially for those with high-risk features.
Beijing, Beijing MunicipalityAges 18–80 - NCT07257640RecruitingPhase 1
IL-5 CAR-T therapy for eosinophilic leukemia
This phase 1 trial tests a new treatment called IL-5 CAR-T for patients with eosinophilic leukemia that has not responded to or has returned after standard therapy. It uses your own immune cells that are modified to target and kill cancer cells that have a specific marker called CD125.
Hangzhou, ZhejiangAges 18 years+ - NCT07260370Recruiting
Studying blood markers in cancer patients on immunotherapy
This study looks at tiny particles (microRNA) and cancer cells in the blood of people with cancer who are getting immunotherapy. It aims to find patterns that might help doctors better understand how the treatment is working.
Taoyuan CityAges 20 years+ - NCT07260812RecruitingPhase 1
KSV01 injection for relapsed DLBCL
This study tests a new injection called KSV01 for people with a type of lymphoma (DLBCL) that has returned or not responded to previous treatments. The goal is to see if it can help shrink tumors or stop the disease from getting worse.
Wuhan, HubeiAges 18–65
Hear when a new T Cells trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for t cells?
- Yes. Clin2 currently lists 5,682 recruiting t cells studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a t cells trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a t cells trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.